Dyne Therapeutics, Inc.
z-rostudirsen
Duchenne muscular dystrophy
Resolved
188days ago
Phase 1 readout · ~ Dec 31, 2025 estimated
What's at stake
Phase 1 trial results for z-rostudirsen in Duchenne muscular dystrophy are due ~ Dec 31, 2025. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“In December 2025, Dyne reported that the REC (n=32) met its primary endpoint, demonstrating a statistically significant change from baseline in muscle content-adjusted 1 dystrophin expression to 5.46% of normal at six months (p<0.0001), a 7”